… widened the prospects of targeting oncogenic protein-protein interfaces enabling the use of
… Taming oncogenic signaling requires a deep understanding of protein interactions and their …

… The huge diversity of PPIs and corresponding protein–protein interfaces means that it is …
protein–protein interface brings to mind the large surfaces that are present in globular protein …

… Targeting protein-protein interface has been difficult in the past due to several reasons. The
interaction surface is often smooth and void of any clefts and pockets for drug binding. The …

… are 17,351 human interfaces (human PPIs) and 4,762 distinct human proteins in these PPIs.
Two hundred and forty-five of these 4,762 human proteins are known oncogenes and tumor …

… proteins that are believed to be oncogenic. Point mutations that reside primarily at the interfaces
of … I/II interface, and P545L and G574V at the domain II/IV interface. These mutations are …

… They may function in “reverse signaling” since the region common to all transmembrane
NRG1s appears to associate specifically with certain cytoplasmic signaling proteins (D. Falls, …

… protein–protein interface dataset that is clustered based on structural similarity for drug
repurposing. We preferred studying protein–protein interfaces … as oncogenic mutations in these …

… Oncogenic activation of the PI3K–AKT pathway in cancer … the potential consequences from
oncogenic PI3K–AKT signalling, … cells with oncogenic PI3K signalling share this vulnerability. …

… see as much signal for the downstream genes as in the α-interface mutant. Together, …
signaling thus can be used to abate MAPK oncogenic activity of Ras. Both ERK and Akt signaling …

… Using mutant proteins and structural biologic approaches, we define a PA2G4–MYCN
protein–protein interface that can be inhibited by a known PA2G4-binding compound, with …